JPRN-jRCT2080225226
Completed
N/A
A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation
oxo Oncology, Inc.,Wholly owned subsidiary of Eli Lilly and Company / CMIC Co., Ltd.0 sites50 target enrollmentJune 11, 2020
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- ocally advanced or metastatic solid tumors with activating RET alterations (and other evidence of RET activation).
- Sponsor
- oxo Oncology, Inc.,Wholly owned subsidiary of Eli Lilly and Company / CMIC Co., Ltd.
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib.
Exclusion Criteria
- •Currently enrolled in an ongoing clinical study of selpercatinib or another RET inhibitor.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
Phase 1
A multiple center expanded access program (EAP) for the treatments of patients with advanced solid tumorsEUCTR2019-002319-25-ITOXO ONCOLOGY INCORPORATED450
Active, Not Recruiting
N/A
An expanded access program of ranibizumab in patients with visual impairment due to diabetic macular edema for whom no suitable therapeutic alternatives exist.EUCTR2011-002731-26-ITOVARTIS FARMA700
Active, Not Recruiting
Phase 1
Access Program for Asfotase AlfaEUCTR2015-000809-39-FRAlexion Pharma International Sàrl100
Completed
N/A
MULTICENTER PROGRAM EXTENDED OPEN MODALITY OF ACCESS WITH ALPHA 2A (RO 25-8310) AS A MONOTERAPY AND COMBINATION THERAPY WITH RIVABIRIN (RO 20-9963) IN PATIENTS WITH CHRONIC HEPATITIS C-B171 Acute hepatitis CAcute hepatitis CB171PER-067-01PRODUCTOS ROCHE Q.F.S.A.,
Approved
N/A
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing ChemotherapyUrothelial CarcinomaNCT02589717Genentech, Inc.